New combo aims to shield bone marrow in tough breast cancer
NCT ID NCT07255612
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This phase 2 trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow in people with advanced triple-negative breast cancer who have already tried at least two prior chemotherapies. The study will enroll 29 participants and measure how often severe low white blood cell counts occur. The goal is to reduce infections and other side effects from chemo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trilaciclib and eribulin
What this could lead to
If successful, this could offer a way to reduce severe side effects from chemotherapy, allowing patients to complete treatment with less bone marrow damage.
What could go wrong
This is a small, early-phase study with only 29 participants, so results may not apply broadly. The combination may not work as hoped or could cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.